Publications in collaboration with researchers from KU Leuven (2)

2020

  1. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

    Lung Cancer, Vol. 147, pp. 137-142

  2. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

    Journal of Thoracic Oncology